Recludix Pharma
Biotechnology company focused on discovering and developing oral small-molecule inhibitors that target SH2 protein domains for inflammatory diseases and oncology. Uses an integrated discovery platform combining custom DNA-encoded libraries, high-throughput structure-activity analysis, structure-based design and family-wide selectivity screening. Advancing multiple programs including a STAT6 SH2 inhibitor in early clinical development and a BTK SH2 inhibitor in preclinical stages; engaged in strategic collaborations to support development.
Industries
Nr. of Employees
medium (51-250)
Recludix Pharma
San Diego, California, United States, North America
Patents
Products
REX-8756 (STAT6 SH2 inhibitor)
Oral, reversible, orthosteric small-molecule inhibitor of the STAT6 SH2 domain developed for Th2-driven inflammatory diseases; reported to have progressed to Phase 1 clinical testing (single- and multiple-ascending-dose cohorts) and to have received IND clearance.
BTK SH2 domain inhibitor program
Program focused on highly selective small-molecule inhibitors targeting the BTK SH2 domain with reported preclinical activity in models relevant to chronic spontaneous urticaria and neuroinflammation; approach aims to inhibit BTK scaffolding function with improved selectivity versus kinase-domain targeted approaches.
REX-8756 (STAT6 SH2 inhibitor)
Oral, reversible, orthosteric small-molecule inhibitor of the STAT6 SH2 domain developed for Th2-driven inflammatory diseases; reported to have progressed to Phase 1 clinical testing (single- and multiple-ascending-dose cohorts) and to have received IND clearance.
BTK SH2 domain inhibitor program
Program focused on highly selective small-molecule inhibitors targeting the BTK SH2 domain with reported preclinical activity in models relevant to chronic spontaneous urticaria and neuroinflammation; approach aims to inhibit BTK scaffolding function with improved selectivity versus kinase-domain targeted approaches.
Services
Integrated discovery service combining custom DEL design, DEL selection and quantitative analysis, structure-based design, co-crystallography and family-wide selectivity profiling to discover selective small-molecule inhibitors of SH2 domains.
Integrated discovery service combining custom DEL design, DEL selection and quantitative analysis, structure-based design, co-crystallography and family-wide selectivity profiling to discover selective small-molecule inhibitors of SH2 domains.
Expertise Areas
- SH2 domain-targeted small-molecule discovery
- DNA-encoded library (DEL) discovery and screening
- Structure-based drug design and crystallography
- Quantitative SAR and DEL data analytics
Key Technologies
- DNA-encoded libraries (DELs)
- Massively parallel SAR determination
- Quantitative DEL selection analytics
- High-resolution small-molecule co-crystallography
News & Updates
Company presentations and webcasts at healthcare and scientific conferences (examples: Oppenheimer, J.P. Morgan, RBC, Stifel, SID).
Corporate presentation materials and media coverage summaries linked from the company's news page.
Reported FDA clearance of an Investigational New Drug application to initiate clinical testing of the oral STAT6 inhibitor.
Reported dosing of first subjects in a blinded Phase 1 study of the oral STAT6 inhibitor and receipt of an associated milestone payment under a collaboration.
Entered into a strategic collaboration with a global pharmaceutical company to develop and commercialize oral STAT6 inhibitors, including milestone and potential transaction terms reported.
Announced nomination of a development candidate for an oral STAT6 inhibitor and achievement of a collaboration milestone.
Company presentations and webcasts at healthcare and scientific conferences (examples: Oppenheimer, J.P. Morgan, RBC, Stifel, SID).
Corporate presentation materials and media coverage summaries linked from the company's news page.
Reported FDA clearance of an Investigational New Drug application to initiate clinical testing of the oral STAT6 inhibitor.
Reported dosing of first subjects in a blinded Phase 1 study of the oral STAT6 inhibitor and receipt of an associated milestone payment under a collaboration.
Entered into a strategic collaboration with a global pharmaceutical company to develop and commercialize oral STAT6 inhibitors, including milestone and potential transaction terms reported.
Announced nomination of a development candidate for an oral STAT6 inhibitor and achievement of a collaboration milestone.